



CAMPBELL & LEVINE, LLC  
Douglas A. Campbell (PA I.D. No. 23143)  
Jeanne S. Lofgren (PA I.D. No. 89078)  
310 Grant Street, Suite 1700  
Pittsburgh, PA 15219  
Telephone: 412.261.0310  
Email: [dcampbell@camlev.com](mailto:dcampbell@camlev.com)  
[jlofgren@camlev.com](mailto:jlofgren@camlev.com)

*General Counsel to the National Opioid Abatement  
Trust II*

# EXHIBIT 1



from NOAT II's Effective Date (defined below) through December 31, 2022 (the "Reporting Period").<sup>2</sup>

Section 2.4 of the Trust Agreement provides:

Within one hundred and twenty (120) days following the end of each calendar year, the Trustees shall file with the Bankruptcy Court the Annual Report audited by the Independent Auditors and accompanied by an opinion of such firm as to the fairness in all material respects of the special-purpose financial statements.

Section 2.5 of the Trust Agreement further provides:

Within one hundred and twenty (120) days following the end of each calendar year, the Trustees shall cause to be prepared and filed with the Bankruptcy Court an annual report on the Approved Opioid Abatement Uses with respect to such period, together with such additional information as the trustees determine necessary or appropriate in their discretion (each, a "NOAT II Opioid Abatement Report").

NOAT II's governing documents require that States and Qualifying Block Grantees shall provide NOAT II with any information reasonably required to satisfy the requirement of the Annual Report and NOAT II Opioid Abatement Report. See Section 7 of the TDP; see also Trust Agreement, Section 2.6(a) and (b).

## II. BACKGROUND

On the Petition Date, the Debtors filed voluntary petitions for relief under chapter 11 of the Bankruptcy Code, 11 U.S.C. § 101, *et seq.* in the Bankruptcy Court. On March 2, 2022, the Bankruptcy Court issued findings of fact and conclusions of law and entered an order confirming the Plan. On June 16, 2022 (the "Effective Date"), the Plan became effective and the Trustees began to operate NOAT II.

---

<sup>2</sup> Capitalized terms not otherwise defined in the 2022 Reports shall have the meaning given to them in the Trust Agreement.

The purposes of NOAT II include assuming all liability for State Opioid Claims and Municipal Opioid Claims and making Abatement Distributions to Authorized Recipients for Approved Uses in accordance with the NOAT II TDP. See Section 1.2 of the Trust Agreement.

On or after the Effective Date, NOAT II received the Aggregate NOAT II Consideration as provided for in Section 3.4 of the Master Trust Distribution Procedures. From the Aggregate NOAT II Consideration, NOAT II established the NOAT II Operating Reserve in accordance with Section 1.2 of the Trust Agreement. The remainder of the Aggregate NOAT II Consideration will fund Abatement Distributions to Authorized Recipients for Approved Uses.

### III. TRUST ADMINISTRATION

Professor David Hickton, Dr. Megan Ranney, and the Honorable Gerald Bruce Lee (Ret.) served as the Trustees of NOAT II. Professor Hickton served as the Managing Trustee during the Reporting Period.

During the Reporting Period, the Trustees held regular meetings in accordance with the requirements of the Trust Agreement. Additionally, the Trustees met individually with Trust advisors, held special meetings, and devoted consistent time to reviewing, commenting, and approving various Trust matters outside of the scheduled meetings.

### IV. ABATEMENT DISTRIBUTIONS

On June 19, 2022, three days after the Effective Date, NOAT II's website was made publicly available and the portal became available for the submission of Statewide Abatement Agreements ("SAAs") and Government Participation Mechanisms ("GPMs"). In accordance with the NOAT II governing documents, the SAA Filing Deadline occurred on August 15, 2022 and the deadline for eligible Qualifying Local Governments to elect to receive a Local Government Block Grant occurred on October 14, 2022. NOAT II continued to receive SAAs

and GPMs through the end of calendar year 2022 and the first quarter of 2023, as permitted by the NOAT II governing documents.

During the third and fourth quarter of 2022, NOAT II reviewed SAAs, GPMs, and QBG elections as they were received, applied allocation models, calculated distributions, and provided beneficiaries with notices of proposed distribution. NOAT II engaged in discussions with beneficiaries to clarify allocations, and addressed related distribution matters when appropriate. NOAT II also set March 1, 2023 as the deadline for the submission of Beneficiary Abatement Use Reports for NOAT II Funds received by NOAT II Beneficiaries during the Reporting Period.

On November 11, 2022, NOAT II provided public Notices of Abatement Distribution on the NOAT II website for four states and one territory. Following expiration of the notice period and objection deadline, NOAT II made Abatement Distributions to those four states and one territory on November 23, 2022. No further Abatement Distributions were made in calendar year 2022. Starting in January 2023, NOAT II has continued making Abatement Distributions at least once per month on a rolling basis.

Due to the relatively short period of time between receipt of the 2022 Abatement Distributions by NOAT II Beneficiaries and the close of the Reporting Period, the 2022 NOAT II Opioid Abatement Report has been simplified and is attached hereto as Exhibit "A."

V. FINANCIAL INFORMATION

NOAT II's audited financial statements for the Reporting Period are attached hereto as Exhibit "B." The financial statements were audited by BDO USA, LLP.

Dated: April 28, 2023  
Wilmington, Delaware

Respectfully submitted,

CAMPBELL & LEVINE, LLC

/s/ Kathleen Campbell Davis

Kathleen Campbell Davis (I.D. No. 4229)

222 Delaware Avenue, Suite 1620

Wilmington, DE 19801

Telephone: 302.426.1900

Email: [kdavis@camlev.com](mailto:kdavis@camlev.com)

-and-

CAMPBELL & LEVINE, LLC

Douglas A. Campbell (PA I.D. No. 23143)

Jeanne S. Lofgren (PA I.D. No. 89078)

310 Grant Street, Suite 1700

Pittsburgh, PA 15219

Telephone: 412.261.0310

Email: [dcampbell@camlev.com](mailto:dcampbell@camlev.com)

[jlofgren@camlev.com](mailto:jlofgren@camlev.com)

*General Counsel to the National Opioid Abatement  
Trust II*



**EXHIBIT A**

## NOAT II OPIOID ABATEMENT REPORT

- [A] Period Covered by Report: Calendar Year 2022
- [B] Total NOAT II Abatement Distributions Disbursed by the Trust during the Covered Period: **\$7,834,280.09**  
See Annex 1 for the list of calendar year 2022 NOAT II Abatement Distributions by NOAT II Beneficiary.
- [C] Total NOAT II Abatement Distributions Disbursed by NOAT II Beneficiaries during the Covered Period: **\$0.00**
- [C.1] Percentage of NOAT II Abatement Distributions Disbursed by NOAT II Beneficiaries during the Covered Period on Approved Opioid Abatement Uses: **0.00%**
- [C.2] Percentage of NOAT II Abatement Distributions Disbursed by NOAT II Beneficiaries during the Covered Period on Approved Administrative Expenses: **0.00%**
- [E] This NOAT II Opioid Abatement Report is provided by the NOAT II Trustees in accordance with the NOAT II governing documents.

### NATIONAL OPIOID ABATEMENT TRUST II



Signature:

David Hickton

Apr 26, 2023 12:01 PM EDT

Name:

**David J. Hickton**

Title:

**Managing Trustee**

Date:

**April 26, 2023**

**ANNUAL REPORT  
NOAT II OPIOID ABATEMENT REPORT  
Annex 1.**

<b>Beneficiary Name</b>	<b>Reference No.</b>	<b>Disbursement Date</b>	<b>Total Amount Disbursed</b>	<b>NOAT II Beneficiary Abatement Use Report Provided by Beneficiary</b>
Guam	20221123B2Q8921C001945	11/23/2022	\$73,496.08	✓
Indiana	20221123B2Q8921C001950	11/23/2022	\$3,391,846.76	✓
Kansas	20221123B2Q8921C001949	11/23/2022	\$1,199,641.39	✓
Mississippi	20221123B2Q8921C001946	11/23/2022	\$1,319,522.16	✓
Nevada	20221123B2Q8921C001948	11/23/2022	\$1,849,773.70	✓
<b>Total Amount of NOAT II Funds Disbursed in Calendar Year 2022</b>			<b>\$7,834,280.09</b>	

**EXHIBIT B**

## National Opioid Abatement Trust II

Special-Purpose Financial Statements  
with Supplementary Information  
For the Period from June 16, 2022 (Inception)  
through December 31, 2022

## **National Opioid Abatement Trust II**

---

Audited Special-Purpose Financial Statements  
With Supplementary Information  
For the Period from June 16, 2022 (Inception) through December 31, 2022

## National Opioid Abatement Trust II

### Contents

---

Independent Auditor's Report	1-3
<b>Special-Purpose Financial Statements</b>	
Special-Purpose Statement of Assets, Liabilities and Net Assets	4
Special-Purpose Statement of Changes in Net Assets	5
Special-Purpose Statement of Cash Flows	6
Notes to the Special-Purpose Financial Statements	7-10
<b>Supplementary Information</b>	
Independent Auditor's Report on Supplementary Information	11
Supplementary Schedules of Operating Expenses	12



Tel: 703-893-0600  
Fax: 703-893-2766  
www.bdo.com

8401 Greensboro Drive  
Suite 800  
McLean, VA 22102

## Independent Auditor's Report

Trustees  
National Opioid Abatement Trust II  
Wilmington, DE

### ***Opinion***

We have audited the special-purpose financial statements of National Opioid Abatement Trust II (the Trust), which comprise the statement of assets, liabilities and net assets as of December 31, 2022, and the related special-purpose statement of changes in net assets and special-purpose statement of cash flows for the period from June 16, 2022 (inception) through December 31, 2022, and the related notes to the special-purpose financial statements.

In our opinion, the accompanying special-purpose financial statements present fairly, in all material respects, the net assets of the Trust as of December 31, 2022 and the changes in net assets and cash flows for the period from June 16, 2022 (inception) through December 31, 2022, in accordance with the special-purpose basis of accounting described in Note 2 to the special-purpose financial statements.

### ***Basis for Opinion***

We conducted our audit in accordance with auditing standards generally accepted in the United States of America (GAAS). Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Special-Purpose Financial Statements* section of our report. We are required to be independent of the Trust and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

### ***Emphasis of Matter - Basis of Accounting***

We draw attention to Note 2 of the special-purpose basis financial statements which describes the basis of accounting. As described in Note 2, the accompanying special-purpose financial statements were prepared by the Trust on the special-purpose of accounting which is a basis of accounting other than accounting principles generally accepted in the United States of America. As a result, the special-purpose financial statements may not be suitable for another purpose. Our opinion is not modified with respect to this matter.

### ***Responsibilities of Management for the Special-Purpose Financial Statements***

Management is responsible for the preparation and fair presentation of the special-purpose financial statements in accordance with the special-purpose of accounting as described in Note 2 to the special-purpose financial statements. Management is also responsible for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of special-purpose financial statements that are free from material misstatement, whether due to fraud or error.

BDO USA, LLP, a Delaware limited liability partnership, is the U.S. member of BDO International Limited, a UK company limited by guarantee, and forms part of the international BDO network of independent member firms.

BDO is the brand name for the BDO network and for each of the BDO Member Firms.





In preparing the special-purpose financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Trust's ability to continue as a going concern within one year after the date that the special-purpose financial statements are issued or available to be issued.

***Auditor's Responsibilities for the Audit of the Special-Purpose Financial Statements***

Our objectives are to obtain reasonable assurance about whether the special-purpose financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the special-purpose financial statements.

In performing an audit in accordance with GAAS, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the special-purpose financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the special-purpose financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Trust's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the special-purpose financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Trust's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.



*Other Information Included in the Annual Report*

Management is responsible for the other information included in the annual report. The other information comprises the annual report and account of the Trust for the period from June 16, 2022 (inception) through December 31, 2022 but does not include the special-purpose financial statements and our auditor's report thereon. Our opinion on the special-purpose financial statements does not cover the other information, and we do not express an opinion or any form of assurance thereon.

In connection with our audit of the special-purpose financial statements, our responsibility is to read the other information and consider whether a material inconsistency exists between the other information and the special-purpose financial statements, or the other information otherwise appears to be materially misstated. If, based on the work performed, we conclude that an uncorrected material misstatement of the other information exists, we are required to describe it in our report.

*BDO USA, LLP*

McLean, Virginia  
April 26, 2023

## **Special-Purpose Financial Statements**

---

**National Opioid Abatement Trust II****Special-Purpose Statement of Assets, Liabilities and Net Assets**

---

*December 31, 2022*

---

**Assets**

Cash and cash equivalents	\$	170,492,030
Interest receivable		551,736
Funding receivable		3,020,760
Prepaid expense		177,071

---

**Total assets** 174,241,597

---

**Liabilities**

Accounts payable		227,950
------------------	--	---------

---

**Total liabilities** 227,950

---

**Net assets** \$ 174,013,647

---

*See accompanying notes to the special-purpose financial statements.*

**National Opioid Abatement Trust II**  
**Special-Purpose Statement of Changes in Net Assets**

---

*For the Period from June 16, 2022 (inception) through December 31, 2022*

---

**Additions**

Funding	\$	182,170,791
Interest income		2,385,191

---

<b>Total additions</b>		<b>184,555,982</b>
------------------------	--	--------------------

---

**Deductions**

Operating expenses		2,708,055
Opioid claims		7,834,280

---

<b>Total deductions</b>		<b>10,542,335</b>
-------------------------	--	-------------------

---

Increase in net assets		174,013,647
------------------------	--	-------------

**Net assets**

Beginning of the period		-
-------------------------	--	---

---

<b>End of the period</b>	<b>\$</b>	<b>174,013,647</b>
--------------------------	-----------	--------------------

---

*See accompanying notes to the special-purpose financial statements.*

**National Opioid Abatement Trust II**  
**Special-Purpose Statement of Cash Flows**

---

*For the Period from June 16, 2022 (inception) through December 31, 2022*

---

**Cash flows from operating activities:**

Increase in net assets	\$ 174,013,647
Adjustments to increase in net assets to net cash provided by operating activities:	
Interest receivable	(551,736)
Funding receivable	(3,020,760)
Prepaid expense	(177,071)
Accounts payable	227,950
<b>Net cash provided by operating activities</b>	<b>170,492,030</b>
Net increase in cash	170,492,030
Cash and cash equivalents at the beginning of the period	-
<b>Cash and cash equivalents at the end of the period</b>	<b>\$ 170,492,030</b>

*See accompanying notes to the special-purpose financial statements.*

## National Opioid Abatement Trust II

### Notes to the Special-Purpose Financial Statements

---

#### 1. Description and Funding of the Trust

National Opioid Abatement Trust II (the Trust) was formed and became effective on June 16, 2022 pursuant to the Fourth Amended Joint Plan of Reorganization (with Technical Modifications) of Mallinckrodt plc and its Debtor Affiliates (Mallinckrodt) under Chapter 11 of the Bankruptcy Code, dated February 18, 2022 (the Plan). The Trust is intended to qualify as a “qualified settlement fund” within the meaning of Section 1.468B-1 *et seq.* of the Treasury Regulations promulgated under Section 468B of the IRC, and to the extent permitted by law, for state and local income tax purposes.

The Plan provides, inter alia, for the establishment of an Opioid Creditor Trust, as defined, with respect to State Opioid Claims, as defined. As of the Effective Date, defined as June 16, 2022, any and all liability of the Debtors for any and all State Opioid Claims shall automatically be channeled to and assumed by the Trust.

In accordance with the National Opioid Abatement Trust II Agreement (the Trust Agreement), pursuant to the Plan and the Confirmation Order, the Trust shall (i) hold, manage and invest all funds and other Trust Assets (as defined in Section 1.3) received by the Trust from the Opioid MDT II (MDT II) for the benefit of the beneficiaries of the Trust; (ii) hold and maintain the National Opioid Abatement Trust II Operating Reserve (as defined in Section 1.2(g)(ii) below); (iii) administer, process, and resolve all State Opioid Claims and Municipal Opioid Claims in accordance with the National Opioid Abatement Trust II TDP; and (iv) pay all National Opioid Abatement Trust II Operating Expenses as defined in Section 1.2(g)(ii).

The Trust is funded with the consideration prescribed under the terms of the Plan through MDT II (also created under the Plan). Funds will be paid by Mallinckrodt to the MDT II and MDT II will make distributions to the Trust and other public and private creditor trusts. The MDT II consideration to be distributed to the Trust is comprised of initial and deferred cash payments from Mallinckrodt, certain Warrants, and certain other non-cash assets as set forth under the Plan. In general, the recoveries and the timing of proceeds to the Trust from such non-cash assets are uncertain at this time.

In general, the Trust’s aggregate consideration (as defined in the Plan) will be comprised of the following:

- a) 97.1% of the first \$625 million received on account of the Public Opioid Creditor Share Distributable Value.
- b) 97.05% of amounts received in excess of \$625 million and up to and including \$1.25 billion on account of the Public Opioid Creditor Share Distributable Value.
- c) 97% of amounts received in excess of \$1.25 billion on account of the Public Opioid Creditor Share Distributable Value.

The initial cash distribution from MDT II was received by the Trust on June 17, 2022 in the amount of \$178,814,391. Future cash received from MDT II will be recorded when received.

On December 8, 2022, the Warrants were monetized and the Trust expects to receive the cash proceeds associated with the monetization of these Warrants in 2023. The anticipated cash proceeds of the monetization of the Warrants is approximately \$3,020,760, net of expenses incurred of \$335,640. This amount is included as funding receivable in the accompanying special-purpose

## National Opioid Abatement Trust II

### Notes to the Special-Purpose Financial Statements

---

statement of assets, liabilities, and net assets and in funding in the accompanying special-purpose statement of changes in net assets.

The Trust will make opioid claim payments, as set forth in the National Opioid Abatement Trust II Agreement, and in accordance with the National Opioid Abatement Trust II TDP, which provides for the State Beneficiaries and State Allocation Percentages.

The Trust made opioid claims payments of \$7,834,280 during the period from June 16, 2022 (inception) through December 31, 2022.

#### 2. Significant Accounting Policies

##### *Basis of accounting*

The Trust's policy is to prepare its financial statements on a special-purpose accounting methods, which is a comprehensive basis of accounting other than accounting principles generally accepted in the United States of America (U.S. GAAP). The special-purpose accounting method includes the following:

- Assets are generally recorded when they are received by the Trust and expenses are generally recorded when the invoice is received from the vendor. The Trust records interest income when earned, and accordingly records an asset for interest receivable.
- Future fixed liabilities under contractual obligations and other agreements entered into by the Trust are recorded as deductions from net assets in the same period that the invoice for such contractual obligations or agreements are received by the Trust. Under U.S. GAAP, liabilities and contractual obligations are recorded over the period that is benefited by the underlying contract or agreement.
- The full amounts of Opioid Claims will be recorded in the period in which the abatement distributions are paid. Under U.S. GAAP, a liability would be recorded for an estimate of the total opioid claims to be made in accordance with the Trust Agreement and the TDP.
- Income tax expense payments or refunds, when applicable, will be recorded when paid or received. Under U.S. GAAP, a provision for income taxes is recorded based upon income reported for financial statement purposes, and federal and state income taxes both currently payable and changes in deferred taxes due to differences between financial reporting and tax bases of assets and liabilities.

##### *Use of estimates*

The preparation of financial statements in conformity with the special-purpose accounting methods described above requires the Trust to make estimates and assumptions that affect the reported amounts of certain assets and liabilities and the disclosures of contingent assets and liabilities at the date of the special-purpose financial statements, as well as the reported amounts of additions and deductions to the net assets during the reporting period. Actual results could differ from those estimates.



## National Opioid Abatement Trust II

### Notes to the Special-Purpose Financial Statements

---

#### *Cash equivalents*

The Trust considers all highly liquid instruments with original maturities of three months or less to be cash equivalents.

#### *Accrued expenses and accounts payable*

Accrued expenses and accounts payable consist of accruals and outstanding invoices associated with managing the Trust.

#### *Operating expenses*

Operating expenses of the Trust are paid from the net assets when invoices are received.

#### *Income taxes*

The Trust is classified as a Qualified Settlement Fund pursuant to the Internal Revenue Code and Regulations thereunder (the Code). As a result, the Trust is subject to federal income taxes based on modified gross income, as defined by the Code. In the opinion of the Trustees and advisors, the Trust is not subject to state income taxes and, therefore, the special-purpose financial statements do not include any provision or liability for state income taxes.

The Trust records income tax expense (or benefit) associated with amounts payable (or receivable) under current federal income taxes, and does not record a provision for (or benefit from) deferred taxes. Accordingly, there is no provision for deferred taxes associated with any future benefit from the potential use of net operating loss carryforwards to reduce taxable income in future years.

As of December 31, 2022, the Trust has no income taxes payable or receivable. The Trust generated approximately \$323,000 in net operating losses during the period from June 16, 2022 (inception) through December 31, 2022.

In accordance with authoritative guidance on accounting for uncertainty in income taxes issued by the Financial Accounting Standards Board (the FASB), management has evaluated the Trust's tax positions and has concluded that the Company has taken no uncertain tax positions that require adjustment to the special-purpose financial statements to comply with the provisions of this guidance.

#### *Risks and uncertainties*

Certain of the Trust's assets are exposed to credit risk. Cash and cash equivalents are maintained at financial institutions and, at times, balances may exceed federally insured limits. The Trust has never experienced any losses related to these balances. Amounts on deposit in excess of federally insured limits at December 31, 2022, approximate \$170 million.

### **3. Trustees' Fees**

The Trust Agreement describes the compensation to be paid to the Trustees for their services, including out of pocket costs and expenses. During the period from June 16, 2022 (inception) through December 31, 2022, the Trust paid a total of \$379,167 in Trustees fees and expenses.

## National Opioid Abatement Trust II

### Notes to the Special-Purpose Financial Statements

---

#### 4. Contingent Liabilities

The Plan Documents (as defined in the Plan) subject the Trust to certain reimbursement and indemnification obligations that may result in future claims against the Trust. The probability of such claims cannot be reasonably determined. The Trust has obtained insurance for purposes of supporting its obligation to indemnify the Trustees.

#### 5. Subsequent Events

The Trust has evaluated its December 31, 2022 special-purpose financial statements for subsequent events through April 26, 2023, the date the special-purpose financial statements were available to be issued. The Trust is not aware of any subsequent events which would require recognition or disclosure in the special-purpose financial statements.

## Supplementary Information

---



Tel: 703-893-0600  
Fax: 703-893-2766  
www.bdo.com

8401 Greensboro Drive  
Suite 800  
McLean, VA 22102

## Independent Auditor's Report on Supplementary Information

Trustees  
National Opioid Abatement Trust II  
Wilmington, DE

Our audit of the special-purpose financial statements included in the preceding section of this report was conducted for the purpose of forming an opinion on those special-purpose statements as a whole. The supplementary information presented in the following section of this report is presented for purposes of additional analysis and is not a required part of those special-purpose financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the special-purpose financial statements. The information has been subjected to the auditing procedures applied in the audit of the special-purpose financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the special-purpose financial statements or to the special-purpose financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the information is fairly stated in all material respects in relation to the special-purpose financial statements as a whole.

*BDO USA, LLP*

April 26, 2023

BDO USA, LLP, a Delaware limited liability partnership, is the U.S. member of BDO International Limited, a UK company limited by guarantee, and forms part of the international BDO network of independent member firms.

BDO is the brand name for the BDO network and for each of the BDO Member Firms.

**National Opioid Abatement Trust II**  
**Supplementary Schedule of Operating Expenses**

---

*Period from June 16, 2022 through ended December 31, 2022*

---

Legal - general counsel	\$	668,337
Claims processor fees and expenses		501,846
Trustee compensation		379,167
Miscellaneous expense - monetized warrants		335,640
Consulting fees		312,640
Legal - special counsel		284,707
Insurance, data, and other expenses		140,327
Government filing fees - private letter ruling		38,000
Accounting fees		33,490
Annual fee - Wilmington Trust Company		7,500
Legal - DE Statutory trust counsel		6,240
Bank fees		161
<b>Total operating expenses</b>	<b>\$</b>	<b>2,708,055</b>

*See independent auditor's report on supplementary information.*

**IN THE UNITED STATES BANKRUPTCY COURT  
FOR THE DISTRICT OF DELAWARE**

	)	
In re:	)	Chapter 11
	)	
MALLINCKRODT PLC, <i>et al.</i> , <sup>1</sup>	)	Case No. 20-12522 (JTD)
	)	
Debtors.	)	(Jointly Administered)
	)	

**CERTIFICATE OF SERVICE**

I, Kathleen Campbell Davis, of Campbell & Levine, LLC, hereby certify that on April 28, 2023 I caused a copy of the *Notice of Filing of Annual Report and Opioid Abatement Report of the National Opioid Abatement Trust II (NOAT II) for the Fiscal Year Ending December 31, 2022* to be served upon the parties below by electronic mail as shown:

Opioid Master Disbursement Trust II  
Attn: Michael Atkinson  
36 S. Charles Street, Suite 2310  
Baltimore, MD 21201  
Email: [MAtkinson@MDTAdmin.com](mailto:MAtkinson@MDTAdmin.com)  
[JPeacock@MDTAdmin.com](mailto:JPeacock@MDTAdmin.com)  
[AFerazzi@MDTAdmin.com](mailto:AFerazzi@MDTAdmin.com)

David J. Molton, Esquire  
Steven D. Pohl, Esquire  
Gerard Cicero, Esquire  
Brown Rudnick LLP  
7 Times Square  
New York, NY 11036  
Email: [dmolton@brownrudnick.com](mailto:dmolton@brownrudnick.com)  
[spohl@brownrudnick.com](mailto:spohl@brownrudnick.com)  
[gcicero@brownrudnick.com](mailto:gcicero@brownrudnick.com)

Dated: April 28, 2023  
Wilmington, Delaware

Respectfully submitted,

CAMPBELL & LEVINE, LLC

/s/ Kathleen Campbell Davis  
Kathleen Campbell Davis (I.D. No. 4229)  
222 Delaware Avenue, Suite 1620  
Wilmington, DE 19801  
Telephone: 302.426.1900  
Email: [kdavis@camlev.com](mailto:kdavis@camlev.com)

*General Counsel to the National Opioid Abatement  
Trust II*

<sup>1</sup> A complete list of the Debtors in these Chapter 11 Cases may be obtained on the website of the Debtors' claims and noticing agent at <http://restructuring.primeclerk.com/Mallinckrodt>. The Debtors' mailing address is 675 McDonnell Blvd., Hazelwood, Missouri 63042.